MedLite ID is Awarded Three U.S. Patents, Applies for Six International Patents

MedLite ID is a company launching from the Dixie State University Atwood Innovation Plaza.

MedLite ID has been awarded three broad utility patents covering all aspects of incorporating any method of lighting of an infusion line. In addition, a fourth patent is currently pending.

In a first for any company incubating at the Atwood Innovation Plaza, MedLite ID has also applied for six foreign patents in China, South Korea, Australia, Canada, Europe, and Japan.

MedLite ID improves patient safety by reducing the risk of errors and cross contamination by replacing the current decades-old practice of using tape and a Sharpie to identify the primary line.

Recently, MedLite ID acquired multiple new and used rolls of medical tape from a healthcare facility and sent them to Soft Cell Biological Research and asked them to culture the random rolls of tape used within a medical facility for bacteria and fungi. While bacteria are prevalent in all environments, multiple antibiotic resistant pathogens should be of concern within any healthcare facility. The results showed that 80% of the rolls tested positive for pathogens and 16 of the 36 bacteria and fugus found were pathogenic. Three of the pathogens were listed on the World Health Organization’s as critical or serious. Learn more:

In addition, MedLite ID can help to reduce clinician’s exposure to COVID-19. According to a study conducted by Dixie State University School of Nursing, MedLite ID reduces the time it takes to trace the primary / emergency medication infusion line by 1-2 minutes per patient, per line tracing. Based on an average of eight IV lines, this could reduce a 16-bed intensive care unit’s exposure to COVID-19 by up to two hours per 12-hour shift. Learn more:

MedLite ID had previously announced a partnership with VHSS, a service-disabled, veteran-owned small business (SDVOSB) and anticipates sales efforts to begin into government healthcare facilities by the end of August. The launch had been delayed due COVID-19 facility lockdowns.